Accessibility Menu
Cadrenal Therapeutics logo

Cadrenal Therapeutics(NASDAQ) CVKD

Current Price$1.90
Market Cap$6.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-97%
5 YearN/A
1 Year-83%
1 Month-34%
Cadrenal Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 2.032026-07-23
Cadrenal Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-12.88%USD 2.332026-07-16
1 month-33.66%USD 3.062026-06-23
3 month-63.09%USD 5.502026-04-24
Year to date-70.06%USD 6.782025-12-31
1 year-82.68%USD 11.722025-07-23
3 year-87.21%USD 15.872023-07-24
Since inception-96.6%USD 61.802023-01-20

Cadrenal Therapeutics Financials at a Glance

Market Cap

$6.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$11.89M

EPS (TTM)

-$5.63

P/E Ratio

-0.37

Dividend

$0.00

Beta (Volatility)

1.20 (Average)

Price

$1.90

Volume

738

Open

$2.06

Previous Close

$1.90

Daily Range

$1.90 - $2.07

52-Week Range

$1.90 - $14.64

Estimated Earnings Date

Aug 10, 2026

CVKD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cadrenal Therapeutics

Cadrenal develops medicines for people with rare blood and immune disorders. Its main drugs aim to help patients with kidney disease or blood clotting problems. These treatments target those with few existing options for care.

Lab Bench to Bedside: Products and Services

  • CAD-1005: Experimental drug for heparin-induced thrombocytopenia, a rare immune reaction to blood thinners (0% of revenue).
  • Tecarfarin: Oral blood thinner for patients with kidney failure or heart pumps (0% of revenue).
  • Frunexian: Intravenous drug for hospital patients at risk of blood clots (0% of revenue).
  • Pipeline R&D: Early-stage drugs for chronic diseases like diabetes and artery disease (0% of revenue).

Growth Spurts and Strategic Moves

  • Acquired Veralox in December 2025, adding CAD-1005 and related drugs.
  • Bought eXIthera in September 2025, expanding into Factor XIa inhibitors.
  • Partnered with Abbott in March 2025 to develop tecarfarin for heart pump patients.
  • Completed manufacturing of tecarfarin for clinical trials in 2025.
  • Plans for a pivotal trial of CAD-1005, pending funding and regulatory review.

Why Cadrenal Is a Bit Different

Cadrenal focuses on rare diseases with few treatment options. Its drugs use new approaches, such as targeting immune pathways instead of just symptoms. The company relies on partnerships and acquisitions to build its pipeline.

Five Things You Need to Know

  • No revenue reported for 2023, 2024, or 2025.
  • Operating loss was $13.5 million in 2025, up 23% from 2024.
  • Cash and equivalents were $4.0 million at December 31, 2025.
  • R&D made up 30.5% of operating expenses in 2025.
  • Only 4 full-time employees, with about 35 consultants and contractors.

Bottom Line

Cadrenal is a young biotech focused on rare blood and immune disorders. It faces high risk but is building a pipeline through acquisitions and partnerships.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

5

CEO

Quang X. Pham

Website

www.cadrenal.com

Headquarters

Ponte Vedra, FL 32082, US

CVKD Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-411.02%

Return on Capital

-491.51%

Return on Assets

-415.38%

Earnings Yield

-2.70%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.10M

Volume

738

Avg. Volume

77.77K

Financials (TTM)

Gross Profit

-$956.00

Operating Income

-$12.05M

EBITDA

-$11.89M

Operating Cash Flow

-$10.96M

Capital Expenditure

-$1.86K

Free Cash Flow

-$10.96M

Cash & ST Invst.

$2.31M

Total Debt

$0.00

Cadrenal Therapeutics Performance Analysis

Cadrenal Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Cadrenal Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Cadrenal Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -8.66N/A
20232023-12-31USD -9.6311.2%
20242024-12-31USD -8.73-9.3%
20252025-12-31USD -6.64-24.0%
Cadrenal Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3010.5%
Q32025-09-3029.9%
Q42025-12-31-7.6%
Q12026-03-3126.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$555.00

+89.9%

Gross Margin

0.00%

N/A

Market Cap

$6.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.30M

N/A

Employees

5

N/A

Net Income

-$2.50M

+35.1%

EBITDA

-$2.50M

+35.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.31M

-68.5%

Total Debt

$0.00

N/A

Accounts Receivable

$5.47K

-77.8%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-4.15%

N/A

Return on Invested Capital

-6.70%

N/A

Free Cash Flow

-$3.00M

+35.5%

Operating Cash Flow

-$3.00M

+35.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SONNSonnet BioTherapeutics Holdings, Inc.
$1.26-59.35%
CLGNCollPlant Biotechnologies Ltd.
$0.31-2.38%
XCURExicure, Inc.
$1.71-2.84%
ITRMIterum Therapeutics plc
$0.03-10.98%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.76-0.29%
NOKNokia
$9.73-0.05%
INTCIntel
$100.23-0.02%
AALAmerican Airlines Group
$13.56-0.08%

Questions About CVKD

What is the current price of Cadrenal Therapeutics?

Cadrenal Therapeutics is trading at $1.90 per share.

What is the 52-week range for Cadrenal Therapeutics?

Over the past 52 weeks, Cadrenal Therapeutics has traded between $1.90 and $14.64.

How much debt does Cadrenal Therapeutics have?

As of the most recent reporting period, Cadrenal Therapeutics reported total debt of $0.00.

How much cash does Cadrenal Therapeutics have on hand?

Cadrenal Therapeutics reported $2.31M in cash and cash equivalents in its most recent financial results.

What is Cadrenal Therapeutics’s dividend yield?

Cadrenal Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services